Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.

Carcinogenesis - 1 Jan 2015

Somyajit Kumar, Mishra Anup, Jameei Aida, Nagaraju Ganesh

Abstract excerpt

Poly (ADP-ribose) polymerase 1 (PARP1) inhibitors are actively under clinical trials for the treatment of breast and ovarian cancers that arise due to mutations in BRCA1 and BRCA2. The RAD51 paralog RAD51C has been identified as a breast and ovarian cancer susceptibility gene. The pathological RAD51C mutants that were identified in cancer patients are hypomorphic with partial repair function. However, targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromatin
Share to Chromosome Aberrations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA End-Joining Repair

Share to Enzyme Inhibitors

Share to Fluorescent Antibody Technique

Share to Genomic Instability

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Identifiers

PMID: 25292178
DOI: 10.1093/carcin/bgu211

Genes

PARP1
BRCA1
BRCA2
RAD51

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.PMID 25292178Read ↗

Recent advancements in PARP inhibitors-based targeted cancer therapySemantic proximity Read ↗

Molecular Pathways: Targeting PARP in Cancer TreatmentSemantic proximity Read ↗

Synthetic Lethality in Cancer: Mechanistic and Therapeutic Insights into PARP Inhibitors, BRCA Mutations, and Homologous Recombination Deficiency (HRD)Semantic proximity Read ↗

Targeting <scp>DNA</scp> damage response in cancer therapySemantic proximity Read ↗

The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatmentSemantic proximity Read ↗

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase InhibitionSemantic proximity Read ↗

The role of PARP in DNA repair and its therapeutic exploitationSemantic proximity Read ↗

Drugging the Cancers Addicted to DNA RepairSemantic proximity Read ↗

RAD51AP1 and RAD54L Can Underpin Two Distinct RAD51-Dependent Routes of DNA Damage Repair via Homologous RecombinationSemantic proximity Read ↗

Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Semantic proximity Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

XRCC8 mutation causes hypersensitivity to PARP inhibition without Homologous recombination repair deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.